15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English 胡黄蓮 & cccDNA
查看: 1943|回复: 18
go

胡黄蓮 & cccDNA [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2012-1-12 13:00 |只看该作者 |倒序浏览 |打印
本帖最后由 风雨不动 于 2012-4-14 14:58 编辑

认识"胡黄莲"的成员请发表评论.
论文来自
stef2011.我们不知道究竟是谁写的论文.

http://www.res-medical.com/chinese-medicine/13274

Inhibitory Effects of Picrosides on Hepatitis B Virus Covalently
Closed Circular DNA in Vitro

Covalently closed circular DNA(cccDNA),serving as the original
template of hepatitis B virus(HBV) replication,is the first
replicative intermediate emerging during the life cycle of
hepadnavirus,which indicates establishment of viral infection and
origination of the replication cycle.A stable pool of cccDNA,has been
found in each nucleus of persistently-infected hepatocyte,and is
thought to be one of the main factors responsible for reoccurrence of
chronic hepatitis B after withdrawal of antiviral agents.
Therefore,determination of HBV cccDNA does not only play an vital role
in the development and evaluation of aritiviral agents,but also may
provide a useful guide to the efficacy of antiviral treatment and the
likelihood of long-term response in patients with hepatitis B,and may
aid in the decision of when to cease therapy.However,poor efficacy has
been achieved aiming at clearance or inhibition of HBV cccDNA with
current anti-HBV therapies,and few visible progresses were made in
drug development and efficacy monitoring work against HBV cccDNA. In
this research,we aimed to confirm the effectiveness and
characteristics of picrosides inhibiting cccDNA in HepG2.2.15
cells,based on the specific and sensitive strategy developed earlier
by our laboratory to determine HBV cccDNA.This research was composed
of three parts:
Ⅰ.Comparative study on the effectiveness and characteristics in inhibiting HBV cccDNA in HepG2.2.15 cells: picrosides versus adefovir dipivoxil.
Ⅱ.Effect of picrosides on the supercoil configuration of HBV cccDNA molecules in HepG2.2.15 cells.
Ⅲ.Effect of picrosides on the transcription of OAS1,STAT2,ISGF3γ,MyD88 and MxA genes in HepG2.2.15 cells

PartⅠ
Inhibitory Effect of Pierosides on Hepatitis B Virus Covalently Closed Circular DNA in HepG2.2.15 Cells
Objectives
To observe the effect of picrosides on HBV cccDNA in HepG2.2.15 cells.
Materials and Methods
HepG2.2.15 cells were separately incubated with culture medium
containing 50μg/ml picrosides,100μg/ml picrosides or 5μg/ml adefovir
dipivoxil for 2 and 5 days.HBV DNA in supernatant,intracellular
cccDNA, intracellular relaxed circular DNA(rcDNA) and pregenomic
RNA(pgRNA) were quantified by specific real-time PCR or RT-PCR.
Results
①Treatment with 50μg/ml picrosides for 2 and 5 days could reduce the
production of HBV in the cell line,as shown by the decline of HBV DNA
in the supernatant(49.74%and 79.48%). Intracellular synthesis of
cccDNA had also been markedly lowered by 43.55%and 56.43%,and
intracellular rcDNA decreased by 43.39%and 63.86%,as well as
intracellular pgRNA decreased by 54.72%and 56.08%.
②Treatment with 100μg/ml picrosides for 2 and 5 days resulted in
decline of HBV DNA(51.11%and 82.07%) in the supernatant,as well as
intracellular cccDNA(41.13%and 57.59%),rcDNA(45.09% and 67.31%) and
pgRNA(52.68%and 52.47%).
③Comparative treatment with adeforvir dipivoxil for 2 and 5 days
resulted in decline of HBV DNA(25.56%and 92.44%) in the
supernatant,cccDNA(18.54%and 47.19%),rcDNA(21.20%and 71.47%) and
pgRNA(11.14%and 37.61%) in HepG2.2.15 cells.
Conclusions Our research indicated that picrosides can interfere with
the replication cycle of HBV, including the formation of cccDNA in
HepG2.2.15 cells.The mechanism of picrosides on cccDNA may differ from
adefovir dipivoxil’s in its earlier inhibition phase.

PartⅡ
Impact of Picrosides on the Distribution of Supercoils inside
Hepatitis B Virus cccDNA in HepG2.2.15 Cells
Objectives
To observe the distribution of superhelixes inside HBV cccDNA
molecules in HepG2.2.15 cells and the effect of picrosides or adefovir
dipivoxil on such distribution.
Materials and Methods
HepG2.2.15 cells were divided into 3 groups: Cells of normal control
group were incubated with fresh complete culture medium, while the
other two groups were incubated with culture medium containing 50μg/ml
picrosides or 5μg/ml adefovir dipivoxil respectively for 2 and 5
days.HBV cccDNA molecules were extracted from HepG2.2.15 cells by
methods based on Hirt-fractionation and then divided into different
groups according to the distinct number of innate superhelixes inside
each cccDNA molecule through special two-dimensional gel
electrophoresis process.Heterogeneous groups of cccDNA with different
superhelix number were detected with 32P-dCTP labeled cccDNA probe
after transfer from gels to nitrocellulose blotting membranes by the
Southern procedure. Integral gray values of different groups,named as
A(containing 0-5 supercoils),B (containing 6-10
supercoils),C(containing 11-15 supercoils) and D(containing 16-20
supercoils) were converted into percentage value and then analyzed
with nonparametric test.
Results
①The median percentage values of A to D distribution group in
picrosides group on day 2 were 14.94%,33.32%,35.96%and
14.05%,respectively; while in adefovir dipivoxil group they were
13.00%,20.04%,25.55%and 39.04%and 12.36%,21.04%,23.22%and 40.77%in
normal control group.The distribution of HBV cccDNA superhelixes in
picrosides group were significantly different from that in adefovir
dipivoxil group(Nemenyi Test,x1,22=8.28,P<0.01) and normal control
group(x1,32=12.86,P<0.01),while no significant difference was found
between adefovir dipivoxil group and normal control
group(x2,32=2.58,P>0.25).
②The median percentage values of A to D in picrosides group on day 5
were 15.40%,33.48%, 34.47%and 15.07%,respectivel;while in adefovir
dipivoxil group they were 13.30%, 20.52%,23.22%and 42.12%and
13.02%,21.24%,22.91%and 40.61%in normal control group.The distribution
of HBV cccDNA superhelixes in picrosides group were significantly
different from those of adefovir dipivoxil group(Nemenyi
Test,x1,22=9.58, P<0.01) and normal control
group(x1,32=11.61,P<0.01),but no significant difference was found
between adefovir dipivoxil group and normal control group(x2,32=0.86,
P>0.75).
③ The median percentage values of A to D in picrosides group on day 5
were 15.40%,33.48%, 34.47%and 15.07%,respectivel;while in adefovir
dipivoxil group they were 13.30%, 20.52%,23.22%and 42.12%and
13.02%,21.24%,22.91%and 40.61%in normal control group.The distribution
of HBV cccDNA superhelixes in picrosides group were significantly
different from those of adefovir dipivoxil group(Nemenyi
Test,x1,22=9.58, P<0.01) and normal control
group(x1,32=11.61,P<0.01),but no significant difference was found
between adefovir dipivoxil group and normal control group(x2,32=0.86,
P>0.75).
③The distribution of superhelixes inside cccDNA molecules in
HepG2.2.15 cells was found as a heterogeneous population,with group D
showing the maximum percentage(about 40%),group B and C a less
percentage(but both above 20%) and group A the least(less than 15%).No
significant difference was found between data on day 2 and day
5(Mann-Whitney U test,U=0.321,P=0.748).
Conclusions
The distribution of superhelixes numbers inside cccDNA molecules in
HepG2.2.15 cells exists as a heterogeneous population,treatment with
adefovir dipivoxil for 2 days and 5 days imposed no significant effect
on the distribution pattern.Treatment with picrosides reduced the
number of innate supercoils inside HBV cccDNA in HepG2.2.15 cells.
Such alteration may cause subsequent reduction of cccDNA molecular
stability which facilitates the clearance of cccDNA in nucleus.

PartⅢ
Effect of picrosides on the transcription of OAS1,STAT2,ISGF3γ, MyD88
and MxA genes in HepG2.2.15 cells
Objectives
To observe the effect of picrosides on the transcription of some host
genes and its relationship with picrosides’ anti-HBV activity in
HepG2.2.15 Cells.
Materials and Methods
①A group of host genes including 2′,5′-oligoadenylate synthetase
1(OAS1),interferon-stimulated gene factor 3-γ(ISGF3γ),signal
transducer and activator of transcription-2(STAT-2),myeloid
differentiation primary response gene 88(MYD88) and myxovirus
resistance protein A(MxA) were selected as candidate genes according
to their reported activity of decreasing pgRNA.Their mRNA levels with
or without picrosides treatment were quantitated by realtime reverse
transcriptase PCR(RT-PCR) withβ-actin mRNA as internal reference.
②HepG2.2.15 cells were treated with picrosides,and effect of MyD88
gene being silenced by siRNA or not were assessed by quantifying
intracellular HBV pgRNA and MyD88 mRNA level as well as total HBV DNA
in supernatant by realtime PCR.
③MyD88 gene being silenced by siRNA or not,intracellular HBV cccDNA
and MyD88 mRNA level were quantitated by realtime PCR,while the
distribution of superhelixes inside HBV cccDNA was evaluated by
two-dimensional gel electrophoresis.
Results
①Ratio of those candidate gene mRNA levels to normal control were
1.17(OAS1),0.87(STAT2),0.93(ISGF3γ), 5.14(MyD88) and 0.83(MxA).The
transcription of MyD88 gene was significantly activated by picrosides’
treatment(P<0.01),while no significant difference were observed in the
transcription of other candidate genes between groups with or without
picrosides treatement(P>0.05).
②MyD88 siRNA can effectively silence MyD88 gene transcription with a
ratio up to 86.35%,while the inhibition rate of HBV DNA in supernatant
and intracellular pgRNA by picrosides declined to 5.02%and 6.67%
respectively on day 2,indicating the partial block of picrosides’
anti-HBV activity by MyD88 siRNA.
③The inhibition rate of intracellular cccDNA by 2 days’ picrosides
treatment in HepG2.2.15 cells remained as 46.24%in despite of silenced
MyD88 gene transcription(with a ratio up to 85.79%),and the inhibition
rate of intracellular cccDNA in mock-transfection HepG2.2.15 cells was
52.73%.The A,B,C and D distribution pattern of cccDNA superhelixes in
MyD88 siRNA group were 17.08%,33.82%, 34.20%and 14.89%while in normal
control group they were 13.82%,20.44%,23.14% and
42.60%,respectively.The distribution of HBV cccDNA superhelixes in
MyD88 siRNA group were also significantly different from that of
normal control group (Nemenyi Test,x1,32=24.74,P<0.01).

Conclusions
Treatment with picrosides can activate transcription of MyD88 gene and may subsequently induce the degradation of pgRNA through MyD88 pathway,but MyD88 gene might not participate in the rapid, early inhibition of HBV cccDNA by picrosides. The inhibition
effect of picrosides on HBV cccDNA in vitro and the reduction of superhelix number of cccDNA might rely on further activation of other host genes.





(6.合.彩)足球.篮球...各类投注开户下注

第一投注现金网:招代理年薪10万以上:yyu.cc
已有 1 人评分现金 收起 理由
interdetect + 20

总评分: 现金 + 20   查看全部评分

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

2
发表于 2012-1-12 13:00 |只看该作者
http://www.res-medical.com/chinese-medicine/13274

Picrosides的抑制作用,对乙型肝炎病毒共价
闭合环状DNA在体外

共价闭合环状DNA(cccDNA的),原
B型肝炎病毒(HBV)复制的模板,是第一
复制中间的新兴的生命周期期间
嗜肝病毒,这表明病毒感染的建立和
复制cycle.A cccDNA的稳定池首创,已
在每个肝细胞持续感染的细胞核,并
被认为是负责再陷的主要因素之一
慢性乙型肝炎抗病毒药物后撤离。
因此,乙肝病毒cccDNA的决心,不仅发挥了至关重要的作用
aritiviral代理商的发展和评价,但也可能
提供有用的指导抗病毒治疗的疗效和
乙型肝炎患者的长期响应的可能性,并可能
在决定何时停止therapy.However援助,疗效不佳
已经达到清除或抑制乙肝病毒cccDNA的目标与
目前的抗乙肝病毒疗法,少数可见的进展作了
药物开发和疗效监测工作,对乙肝病毒cccDNA.In
这项研究中,我们的目的是确认的有效性和
picrosides抑制cccDNA的特点,在HepG2.2.15细胞
细胞的特异性和敏感性的战略发展较早
我们的实验室,以确定HBV cccDNA.This研究组成
比较研究的有效性和三部分组成:Ⅰ。
HepG2.2.15细胞的抑制乙肝病毒cccDNA的特点:
picrosides与阿德福韦酯。
Ⅱ。影响乙肝病毒cccDNA的超螺旋结构的picrosides
在HepG2.2.15细胞的分子。
Ⅲ影响picrosides OAS1转录,STAT2,ISGF3γ,MyD88的
和MXA HepG2.2.15细胞中的基因

部分Ⅰ
Pierosides抑制对乙型肝炎病毒共价闭合
HepG2.2.15细胞中的环状DNA
目标
观察HepG2.2.15细胞的picrosides对HBV cccDNA的效果。
材料和方法
HepG2.2.15细胞分别培养液中培养
picrosides50μg/ml,100μg/mlpicrosides或5μg/ml阿德福韦
酯为2和5 days.HBV上清,细胞内的DNA
cccDNA的,宽松的细胞内环状DNA(rcDNA)和前基因组
RNA(pgRNA)进行了量化,具体实时PCR或RT - PCR。
结果
①50μg/mlpicrosides 2和第5天的治疗可减少
HBV的细胞株,生产所示的HBV DNA下降
在上清(49.74%和79.48%)。细胞内合成
cccDNA的也得到了显着降低了43.55%和56.43%,并
细胞内rcDNA下降了43.39%和63.86%,以及
细胞内pgRNA下降54.72%和56.08%。
②治疗2和第5天100μg/mlpicrosides导致
上清液中的HBV DNA(51.11%和82.07%)下降,以及
细胞内的cccDNA的(41.13%和57.59%),rcDNA(45.09%和67.31%)和
pgRNA(52.68%和52.47%)。
③比较adeforvir酯治疗2和第5天
导致在HBV DNA的下降(25.56%和92.44%)
上清,cccDNA的(18.54%和47.19%),rcDNA(21.20%和71.47%)和
pgRNA(11.14%和37.61%)在HepG2.2.15细胞。
结论我们的研究表明,picrosides可干扰
对乙肝病毒的复制周期,包括cccDNA的形成
HepG2.2.15细胞cccDNA的picrosides cells.The机制可能不同于
阿德福韦酯在其先前的抑制阶段。

部分Ⅱ
影响分布的超螺旋内的Picrosides
HepG2.2.15细胞中乙型肝炎病毒cccDNA的
目标
观察superhelixes内乙肝病毒cccDNA的分布
HepG2.2.15细胞中的分子和picrosides或阿德福韦的效果
酯对等的分布。
材料和方法
HepG2.2.15细胞分为3组:正常对照组的细胞
组与新鲜的完全培养基孵育,而
其他两组含50μg/ml培养基孵育
picrosides或5μg/ml阿德福韦酯分别为2和5
days.HBV cccDNA的分子分别提取HepG2.2.15细胞
希尔特分离方法的基础上,然后划分成不同的
根据不同的先天superhelixes里面的组
每个通过特殊的双向凝胶cccDNA的分子
具有不同的cccDNA的电泳process.Heterogeneous组
超螺旋数32P - dCTP标记cccDNA的探头检测
从凝胶转移到硝酸纤维素印迹膜后
南程序。积分不同群体的灰度值,命名为
一个(含0-5超螺旋),B(含6-10
超螺旋),C(含11-15超螺旋)和D(含16-20
百分比值转换成超螺旋),然后分析
非参数检验。
结果
①A至D通讯组的中位数百分比值
picrosides组第2天分别为14.94%,33.32%,35.96%和
14.05%,而阿德福韦组
13.00%,20.04%,25.55%和39.04%和12.36%,21.04%,23.22%和40.77%
正常对照组的HBV cccDNA的group.The分布superhelixes在
picrosides组均显着不同,在阿德福韦
酯组(Nemenyi测试,X1,22 = 8.28,P <0.01)和正常对照
组(X1,32 = 12.86,P <0.01),而没有显著差异
阿德福韦酯组和正常对照之间
组(X2,32 = 2.58,P> 0.25)。
②A至D的中位数百分比值picrosides组第5天
分别为15.40%,33.48%,34.47%和15.07%respectivel;而在阿德福韦
酯组分别为13.30%,20.52%,23.22%和42.12%,
在正常对照group.The分布的13.02%,21.24%,22.91%和40.61%
乙肝病毒cccDNA的picrosides superhelixes组均显着
不同于阿德福韦酯组(Nemenyi
测试,X1,22 = 9.58,P <0.01)和正常对照
组(X1,32 = 11.61,P <0.01),但无显着性差异被发现
阿德福韦酯组和正常对照组(X2,32 = 0.86之间,
P <0.75)。
③A至D的中位数百分比值picrosides组第5天
分别为15.40%,33.48%,34.47%和15.07%respectivel;而在阿德福韦
酯组分别为13.30%,20.52%,23.22%和42.12%,
在正常对照group.The分布的13.02%,21.24%,22.91%和40.61%
乙肝病毒cccDNA的picrosides superhelixes组均显着
不同于阿德福韦酯组(Nemenyi
测试,X1,22 = 9.58,P <0.01)和正常对照
组(X1,32 = 11.61,P <0.01),但无显着性差异被发现
阿德福韦酯组和正常对照组(X2,32 = 0.86之间,
P <0.75)。
③内cccDNA的分子分布在superhelixes
作为一个异类人口,与D组HepG2.2.15细胞被发现
显示最大百分比(约40%),B组和C较少
百分比(但均在20%以上)和A组(小于15%)。
发现数据之间的差异有显着性,第2天及日间
5(采用Mann - Whitney U检验,U = 0.321,P = 0.748)。
结论
superhelixes数字cccDNA的分子内的分布
HepG2.2.15细胞中存在一个异构的人口,治疗
阿德福韦酯为2天,5天实行无显着影响
分布pattern.Treatment picrosides减少
在HepG2.2.15细胞内乙肝病毒cccDNA的先天超螺旋。
这种改动可能会导致cccDNA的分子随之减少
稳定,促进细胞核内的cccDNA的间隙。

部分Ⅲ
picrosides OAS1转录,STAT2,ISGF3γ,MyD88的影响
和MXA HepG2.2.15细胞中的基因
目标
观察picrosides上一些主机转录的影响
基因及其picrosides“抗HBV活性的关系
HepG2.2.15细胞。
材料和方法
①A组的宿主基因包括2',5' -寡腺苷酸合成酶
1(OAS1),干扰素刺激基因因子3 -γ(ISGF3γ),信号
传感器和激活转录- 2(STAT - 2),髓
分化的主要响应基因88(MyD88的)和myxovirus
耐药蛋白A(MXA)被选定为候选基因
他们的报告减少pgRNA.Their mRNA水平与活动
picrosides治疗或不定量实时反向
逆转录PCR(RT - PCR技术)withβ- actin基因作为内部参考。
②HepG2.2.15细胞共收治picrosides,MyD88的效果
基因沉默的siRNA或不通过量化评估
细胞内的乙肝病毒pgRNA和MyD88 mRNA水平以及总HBV DNA
通过实时PCR上清。
③MyD88的基因的siRNA沉默与否,细胞内的乙肝病毒cccDNA的
和MyD88 mRNA水平分别定量实时PCR技术,而
乙肝病毒cccDNA的内部superhelixes分配进行了评估
二维凝胶电泳。
结果
①这些候选基因的mRNA水平比正常对照组分别为
1.17(OAS1),0.87(STAT2),0.93(ISGF3γ),5.14(MyD88的)和0.83(MXA)。
MyD88的基因的转录显着激活picrosides“
治疗性(P <0.01),而没有显著差异,在观察
与组之间或没有其他候选基因的转录
picrosides treatement(P> 0.05)。
②MyD88的siRNA能有效地沉默与MyD88的基因转录
比例高达86.35%,而培养上清中的HBV DNA抑制率
picrosides细胞内pgRNA下降5.02%和6.67%
分别于第2天,说明部分picrosides块“
MyD88的siRNA的抗HBV活性。
③细胞内的cccDNA的抑制率2天“picrosides
尽管的沉默,在HepG2.2.15细胞的治疗仍然为46.24%
MyD88的基因转录的比例高达85.79%,且抑制
在模拟转染率细胞内的cccDNA的HepG2.2.15细胞
cccDNA的superhelixes,A,B,C和D的分布格局52.73%。
MyD88的siRNA组分别为17.08%,33.82%,34.20%和14.89%,而在正常
对照组分别为13.82%,20.44%,23.14%和
42.60%,分别为乙肝病毒cccDNA的分布superhelixes在
MyD88的siRNA组也显著的不同
正常对照组(Nemenyi测试,X1,32 = 24.74,P <0.01)。

结论与picrosides治疗可以激活转录
MyD88的基因,并随后可能诱发pgRNA退化
通过MyD88的途径,但MyD88的基因可能不参与
快速,早期抑制乙肝病毒cccDNA的picrosides.The抑制
在体外对HBV cccDNA的picrosides效果和减少
超螺旋cccDNA的数量可能依赖于其他进一步激活
宿主基因。

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

3
发表于 2012-1-12 13:05 |只看该作者
本帖最后由 StephenW 于 2012-1-12 13:05 编辑

Picrosides seems to be extracted from a Himalayian plant:
"Picrorrhiza kurroa Royle ex Benth (Family: Scrophulariaceae) is a
perennial herb, growing primarily in
the north-west Himalayan mountains. Rhizomes and roots of this plant
are widely used for the
treatment of a range of liver diseases (1 & 2). It is reported to have
anti-cancer activity (3 ) and extracts
can be used as selective enhancers of neuron growth (4,5)
The active constituents responsible for the medicinal properties of P. kurroa are mainly picroside-I and picroside –II (Figure 1) but little is known about the biosynthesis of
these iridoid compounds."
(http://www.rothamsted-international.org/files/posters/Posters/sondutt.pdf)

Latin Name Picrorhiza kurroa,Royle. ex Benth. Scrophulariaceae
Sanskrit Name:  Katuka
History
Picrorhiza kurroa
Katuka has a long history of medicinal use, especially in India but
also in China where it is known as hu huang lian. The dried rhizome is
antipyretic, anti-inflammatory, antiperiodic, cathartic (in large
doses), cholagogue, laxative (in smaller doses), carminative and
bitter tonic.
(http://www.himalayahealthcare.com/herbfinder/h_picrorhiza.htm)

hu huang lian胡黄蓮 is a well known herb(?) and has been
studied:http://www.cmjournal.org/content/pdf/1749-8546-6-26.pdf


Picrosides似乎是从Himalayian植物中提取:
“Picrorrhiza kurroa罗伊尔前Benth(家庭:玄参)是一个
多年生草本植物,主要是在不断增长
西北部的喜马拉雅山脉。这种植物的根茎和根
被广泛用于
治疗肝脏疾病的范围(1&2)。据悉有
抗癌活性(3),并提取
可作为选择性神经生长促进剂(4,5)
负责体育的药性的活性成分
kurroa主要是胡黄连苷- I和
胡黄连苷- II(图1),但知之甚少的生物合成
这些环烯醚萜类化合物。“
http://www.rothamsted-international.org/files/posters/Posters/sondutt.pdf

拉丁名:黄连kurroa,罗伊尔。当然Benth。玄参
梵文名:Katuka
历史黄连kurroa
Katuka尤其是在印度的药用历史悠久,但
在中国,它是已知胡黄连。干燥根茎
解热,消炎,反周期,导泻(大
剂量),利胆,通便(小剂量),驱风,
苦进补。
http://www.himalayahealthcare.com/herbfinder/h_picrorhiza.htm



胡黄连胡黄莲是一个众所周知的药草(?),并已
研究:http://www.cmjournal.org/content/pdf/1749-8546-6-26.pdf

Rank: 6Rank: 6

现金
566 元 
精华
帖子
254 
注册时间
2010-12-4 
最后登录
2012-6-5 
4
发表于 2012-1-12 14:25 |只看该作者
回复 StephenW 的帖子

Chinese people's prescription, do not believe ~! Fraudulent, deceptive Chinese scientists in addition to not much head knowledge.
HBV虽然目前还没办法根治,让我们的生活比别人更累了,但是我们不要气垒,乙肝其实并不是别人宣传的那样可怕,只有8%的乙人因为生活不规造成严重肝癌!我们要注意饮食和睡眠就好了,给自己活下去的多一点勇气。加油各位,因为我也在很努力的生活着.........
希望所有乙人不要听人乱讲和乱用药,用药前去公立的大医院挂个号

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

5
发表于 2012-1-12 15:21 |只看该作者
回复 非东亚病夫 的帖子

We don't know who are doing the research. That is why I am asking.

Rank: 6Rank: 6

现金
3423 元 
精华
帖子
1747 
注册时间
2003-12-28 
最后登录
2012-4-14 
6
发表于 2012-1-12 17:54 |只看该作者
StephenW 发表于 2012-1-12 13:00
http://www.res-medical.com/chinese-medicine/13274

Picrosides的抑制作用,对乙型肝炎病毒共价

这翻译的。。。。
是工具翻的吧。。。。
-------------------------------------------------------------------------- 静静的村庄飘着白的雪 阴黧的天空下鸽子在飞翔 白桦树刻着那两个名字 他们发誓相爱用尽一生 有一天战火烧到了家乡 小伙子拿起枪奔赴边疆。。。。。。。

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

7
发表于 2012-1-12 20:22 |只看该作者
本帖最后由 StephenW 于 2012-1-12 20:23 编辑

回复 广羽 的帖子

是的,谷歌翻译, 我认为是先进的,但不能充分履行科学文献翻译.

Rank: 6Rank: 6

现金
3423 元 
精华
帖子
1747 
注册时间
2003-12-28 
最后登录
2012-4-14 
8
发表于 2012-1-12 20:33 |只看该作者
StephenW 发表于 2012-1-12 20:22
回复 广羽 的帖子

是的,谷歌翻译, 我认为是先进的,但不能充分履行科学文献翻译. ...

我个人认为不能完全否认中医!
-------------------------------------------------------------------------- 静静的村庄飘着白的雪 阴黧的天空下鸽子在飞翔 白桦树刻着那两个名字 他们发誓相爱用尽一生 有一天战火烧到了家乡 小伙子拿起枪奔赴边疆。。。。。。。

Rank: 6Rank: 6

现金
3423 元 
精华
帖子
1747 
注册时间
2003-12-28 
最后登录
2012-4-14 
9
发表于 2012-1-12 20:33 |只看该作者
客观看待一切问题,如果不能客观,我认为背后有原因
-------------------------------------------------------------------------- 静静的村庄飘着白的雪 阴黧的天空下鸽子在飞翔 白桦树刻着那两个名字 他们发誓相爱用尽一生 有一天战火烧到了家乡 小伙子拿起枪奔赴边疆。。。。。。。

Rank: 4

现金
155 元 
精华
帖子
101 
注册时间
2008-6-12 
最后登录
2017-12-7 
10
发表于 2012-1-13 00:46 |只看该作者
StephenW 发表于 2012-1-12 15:21
回复 非东亚病夫 的帖子

We don't know who are doing the research. That is why I am asking.

You don't know how to use Google search? Just input "胡黄连,乙肝病毒",就知道原作者是谁了,原来是中国研究者写的文章:

胡黄连对乙型肝炎病毒抑制作用的实验研究



高华  周亚伟  



【摘要】:正 目的:阐明胡黄连抑制乙肝病毒的作用。方法1)感染乙型肝炎病毒鸭,在感染后第7天口服给不同剂量的胡黄连(30、60、120mg/kg)治疗,观察其血清DHBV-DNA水平(OD值)。(2)HepG2.2.15细胞与不同剂量的胡黄连(0.5、0.25、0.125、0.0625mg/ml)共同培养,第8天测定其细胞抑制率及对乙肝表面抗原(HBsAg)和e抗原(HBeAg)的影响,并与阳性药物阿昔洛



【作者单位】:北京大学世佳研究中心 北京大学化学与分子工程学院
【分类号】:R285.5
【正文快照】:

目的;阐明胡黄连抑制乙肝病毒的作用。方法1)感染乙型肝炎病毒鸭.在感染后第7天口服给不同剂量的胡黄连(30、60、120mg/kg)治疗,观察其血清D卜IBV—DNA水平(0D值)。(2)l_IepG2。2。15细胞与不同剂量的胡黄连(O.5、O.25、0.125、O.0625mg/m1)共同培养,第8天测定其细胞抑制率



‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-11-1 10:33 , Processed in 0.016029 second(s), 12 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.